"Harringtonines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.
| Descriptor ID |
D006248
|
| MeSH Number(s) |
D03.132.420 D03.633.100.079.533 D03.633.400.624
|
| Concept/Terms |
Harringtonines- Harringtonines
- Cephalotaxine Alkaloids
- Alkaloids, Cephalotaxine
- Cephalotaxus Alkaloids
- Alkaloids, Cephalotaxus
|
Below are MeSH descriptors whose meaning is more general than "Harringtonines".
Below are MeSH descriptors whose meaning is more specific than "Harringtonines".
This graph shows the total number of publications written about "Harringtonines" by people in this website by year, and whether "Harringtonines" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Harringtonines" by people in Profiles.
-
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21.
-
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
-
Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013 Oct; 14(14):1977-86.
-
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):530-3.
-
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul; 98(7):e78-9.
-
Is there a standard induction regimen for patients with AML? Lancet Oncol. 2013 Jun; 14(7):565-6.
-
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011 Jan 06; 117(1):156-64.
-
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 01; 115(23):5382-93.
-
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol. 2009 Apr; 84(4):256-7.
-
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs. 2008 May; 11(5):356-72.